These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8915491)
1. Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Yang JL; Ow KT; Russell PJ; Ham JM; Crowe PJ Ann Surg Oncol; 1996 Nov; 3(6):574-9. PubMed ID: 8915491 [TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Sun XF; Carstensen JM; Stål O; Zhang H; Nordenskjöld B Int J Cancer; 1996 Feb; 69(1):5-8. PubMed ID: 8600060 [TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach. Saegusa M; Takano Y; Kishimoto H; Wakabayashi G; Nohga K; Okudaira M J Cancer Res Clin Oncol; 1993; 119(12):737-44. PubMed ID: 8104947 [TBL] [Abstract][Full Text] [Related]
4. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
5. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. Crowe PJ; Yang JL; Berney CR; Erskine C; Ham JM; Fisher R; Russell PJ World J Surg; 2001 Aug; 25(8):996-1001. PubMed ID: 11571982 [TBL] [Abstract][Full Text] [Related]
6. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ismail MF; Aly MS; Khaled HM; Mohamed HM Ger Med Sci; 2009 May; 7():Doc03. PubMed ID: 19675743 [TBL] [Abstract][Full Text] [Related]
7. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Volm M; Efferth T; Mattern J Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920 [TBL] [Abstract][Full Text] [Related]
8. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853 [TBL] [Abstract][Full Text] [Related]
9. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Wang DG; Johnston CF; Buchanan KD Cancer; 1997 Aug; 80(4):668-75. PubMed ID: 9264349 [TBL] [Abstract][Full Text] [Related]
10. [Proliferating cell nuclear antigen and p53 protein expression in submucosal invasive colorectal carcinoma]. Kanazawa Y; Onda M; Tanaka N; Seya T J Nippon Med Sch; 2000 Aug; 67(4):242-9. PubMed ID: 10938592 [TBL] [Abstract][Full Text] [Related]